Signaling and the Frontiers Ahead

  • José Marín-García


Signal transduction is a process by which cells convert one kind of signal or stimulus into another. Because of its complexity, the study of cell signaling is of necessity multidisciplinary, using tools from biochemistry, cell biology, structural biology, bioinformatics, and computational biology, together with in vivo and in vitro studies, including cells culture and whole animal models, to address a wide range of questions in cardiovascular medicine; indeed, to probe into some of the core processes that define and regulate life itself. As discussed previously, a number of cardiovascular pathological conditions are associated with defects in the complex structures formed by signaling pathways; however, increasing knowledge of the genetic and molecular changes that occur in cardiovascular diseases, in general, in the complex field of signal transduction pathways is being deciphered. Nevertheless, fundamental questions still remain unanswered regarding the underlying molecular and biochemical mechanisms involved in signaling, and how this information can be used in improving cardiac diagnosis and treatment. To address these questions, emerging technologies are being recruited, some tested so far in animal models and others are being investigated in clinical trials. Novel approaches include the use of molecular genetics, microarrays, proteomics, and integrated systems biology. In this chapter, a discussion on new frontiers in CV signaling is presented.


Integrative cardiology Microarray Genetic biomarkers Modeling system Computational biology 


  1. 1.
    Yaffe MB. Seeing the signaling forest and the trees. Sci Signal. 2008;1:eg5.CrossRefGoogle Scholar
  2. 2.
    Azuaje F, Devaux Y, Wagner DR. Integrative pathway-centric modeling of ventricular dysfunction after myocardial infarction. PLoS One. 2010;5:e9661.PubMedCrossRefGoogle Scholar
  3. 3.
    Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345–52.PubMedGoogle Scholar
  4. 4.
    McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest. 2005;115:538–46.PubMedGoogle Scholar
  5. 5.
    Nanni L, Romualdi C, Maseri A, Lanfranchi G. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J Mol Cell Cardiol. 2006;41:934–48.PubMedCrossRefGoogle Scholar
  6. 6.
    Uchida S, Schneider A, Wiesnet M, et al. An integrated approach for the systematic identification and characterization of heart-enriched genes with unknown functions. BMC Genomics. 2009;10:100.PubMedCrossRefGoogle Scholar
  7. 7.
    Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol. 2003;41:761–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Park M, Shen YT, Gaussin V, et al. Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol. 2009;297:H785–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Stanley BA, Gundry RL, Cotter RJ, Van Eyk JE. Heart disease, clinical proteomics and mass spectrometry. Dis Markers. 2004;20:167–78.PubMedGoogle Scholar
  10. 10.
    Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol. 2005;563:23–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Gujral TS, MacBeath G. Emerging miniaturized proteomic technologies to study cell signaling in clinical samples. Sci Signal. 2009;2:pe65.PubMedCrossRefGoogle Scholar
  12. 12.
    Gutstein HB, Morris JS, Annangudi SP, Sweedler JV. Microproteomics: analysis of protein diversity in small samples. Mass Spectrom Rev. 2008;27:316–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Huang SS, Fraenkel E. Integrating proteomic, transcriptional, and interactome data reveals hidden components of signaling and regulatory networks. Sci Signal. 2009;2:ra40.PubMedCrossRefGoogle Scholar
  14. 14.
    Schwab K, Neumann B, Scheler C, Jungblut PR, Theuring F. Adaptation of proteomic techniques for the identification and characterization of protein species from murine heart. Amino Acids. 2011;41:401–14.Google Scholar
  15. 15.
    Bon E, Steegers R, Steegers EA, et al. Proteomic analyses of the developing chicken cardiovascular system. J Proteome Res. 2010;9:268–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Kittleson MM, Hare JM. Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med. 2005;15:130–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bassingthwaighte JB, Qian H, Li Z. The Cardiome Project. An integrated view of cardiac metabolism and regional mechanical function. Adv Exp Med Biol. 1999;471:541–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Ch’en F, Clarke K, Vaughan-Jones R, Noble D. Modeling of internal pH, ion concentration, and bioenergetic changes during myocardial ischemia. Adv Exp Med Biol. 1997;430:281–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Noble D. Modeling the heart – from genes to cells to the whole organ. Science. 2002;295:1678–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Rudy Y. From genome to physiome: integrative models of cardiac excitation. Ann Biomed Eng. 2000;28:945–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Hunter P, Smith N, Fernandez J, Tawhai M. Integration from proteins to organs: the IUPS Physiome Project. Mech Ageing Dev. 2005;126:187–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Crampin EJ, Halstead M, Hunter P, et al. Computational physiology and the Physiome Project. Exp Physiol. 2004;89:1–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Lipshtat A, Neves SR, Iyengar R. Specification of spatial relationships in directed graphs of cell signaling networks. Ann N Y Acad Sci. 2009;1158:44–56.PubMedCrossRefGoogle Scholar
  24. 24.
    Noble D. Modelling the heart: insights, failures and progress. Bioessays. 2002;24:1155–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Lyengar R. Why we need quantitative dynamic models. Sci Signal. 2009;2:eg3.CrossRefGoogle Scholar
  26. 26.
    Alexander RP, Kim PM, Emonet T, Gerstein MB. Understanding modularity in molecular networks requires dynamics. Sci Signal. 2009;2:pe44.PubMedCrossRefGoogle Scholar
  27. 27.
    Xu TR, Vyshemirsky V, Gormand A, et al. Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal. 2010;3:ra20.CrossRefGoogle Scholar
  28. 28.
    Hlavacek WS, Faeder JR, Blinov ML, Posner RG, Hucka M, Fontana W. Rules for modeling signal-transduction system. Sci STKE. 2006;2006:re6.PubMedCrossRefGoogle Scholar
  29. 29.
    Kreuter M, Langer C, Kerkhoff C, Reddanna P, Kania AL, Maddika S, et al. Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch Immunol Ther Exp (Warsz). 2004;52:141–55.Google Scholar
  30. 30.
    Roth GS, Lane MA, Ingram DK. Caloric restriction mimetics: the next phase. Ann N Y Acad Sci. 2005;1057:365–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Ingram DK, Anson RM, de Cabo R, et al. Development of calorie restriction mimetics as a prolongevity strategy. Ann N Y Acad Sci. 2004;1019:412–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Dirks AJ, Leeuwenburgh C. Caloric restriction in humans: potential pitfalls and health concerns. Mech Ageing Dev. 2006;127:1–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Adler EM. 2009: signaling breakthroughs of the year. Sci Signal. 2010;3:eg1.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.The Molecular Cardiology and Neuromuscular InstituteHighland ParkUSA

Personalised recommendations